The blockade of the PD-1/PD-L1 pathway with immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, especially in malignancies like melanoma, non-small cell lung cancer (NSCLC), and bladder cancer [67,68,69,70]. This evidence concerns the gene CD274 and melanoma.